What Siemens Healthineers actually announced
As of October 12, 2026, Siemens Healthineers stopped selling its general imaging diagnostic ultrasound systems — the Acuson Sequoia, Redwood, Juniper and Maple — according to the company's own press release, first reported by Radiology Business and also covered by AuntMinnie and Becker's Hospital Review.
Existing customers aren't abandoned: the company says it will keep honoring contractual and regulatory obligations and will continue maintenance, software updates and transducer availability for installed general-imaging systems. But no new general-imaging ultrasound units will be sold going forward. In their place, Siemens Healthineers is concentrating the ultrasound business entirely on procedural systems — the Acuson Origin, the P500 intracardiac echocardiography (ICE) system, and Freestyle — sold with dedicated software and catheters to electrophysiologists and interventional cardiologists performing image-guided cardiovascular procedures.
Sourabh Pagaria, head of Siemens Healthineers' ultrasound business, put the rationale plainly: "imaging is increasingly becoming part of therapy, not just diagnosis." The company points to more than 25 years of work in ICE as the foundation for that bet.
The economics behind the exit
Siemens Healthineers has never been a top-tier player in conventional, general-imaging ultrasound — Philips, GE HealthCare, Fujifilm and Canon have long led that market — and coverage of the exit tied that scale disadvantage directly to weaker margins in the segment, per ad-hoc-news, which also put the business's scale at just over €600 million in revenue in 2025 — a sliver of the company's €23.4 billion in total fiscal-2025 revenue across roughly 74,000 employees, per the company's own disclosure.
Procedural ultrasound, by contrast, sits inside a cardiovascular franchise where Siemens Healthineers already has defensible technical share — ICE catheters and the interventional cardiology relationships that go with them aren't a market four other multinationals already dominate. Exiting a low-share, low-margin category to double down on a higher-share, higher-margin one is a straightforward capital-allocation decision, not a clinical judgment about which kind of ultrasound matters more.
It's a segment move, not a one-off
The ultrasound decision lines up with a restructuring Siemens Healthineers announced company-wide in November 2025. Under its "Elevating Health Globally" strategy, the company regrouped its financial reporting into three segments, per its own Capital Markets Day announcement: Imaging (disease prevention and detection), Diagnostics (its own standalone strategy), and a brand-new Precision Therapy segment built around treatment — combining Varian radiation oncology, the existing Advanced Therapies interventional business, and ultrasound.
That new Precision Therapy segment carries the company's most aggressive growth target: high-single-digit annual revenue growth and roughly 100 basis points of margin improvement a year through fiscal 2030, versus a mid-to-high-single-digit growth target with scale-driven margin gains for Imaging. Ultrasound — at just over €600 million — makes up about 9% of that segment's revenue, which is exactly why a low-margin general-imaging tail was expendable: it diluted a business unit management had just told investors would be the company's margin engine. CEO Bernd Montag summed up the broader strategy as wanting to "make an impact on the health of the world's 8 billion people by fighting the diseases they fear" — stroke, cancer, cardiovascular disease and neurodegenerative conditions, all of which lean on procedures, not just diagnosis.
Put those two announcements together and the ultrasound exit stops looking like a product-line prune and starts looking like the segment doing exactly what it was reorganized to do: shed the diagnostic-adjacent piece that didn't fit a therapy-margin target.
| Dimension | General-imaging ultrasound (discontinued) | Procedural ultrasound (continuing) |
|---|---|---|
| Products | Acuson Sequoia, Redwood, Juniper, Maple | Acuson Origin, P500 (ICE), Freestyle |
| Primary buyer | General radiology, OB-GYN, point-of-care clinicians | Electrophysiologists, interventional cardiologists |
| Clinical role | Diagnosis — detect and characterize disease | Live image guidance during a cardiovascular procedure |
| Siemens segment (Nov. 2025 restructuring) | n/a — discontinued | Precision Therapy (with Varian, Advanced Therapies) |
| Competitive position | Scale disadvantage vs. Philips, GE HealthCare, Fujifilm, Canon | Niche leadership, 25+ years in ICE |
Product and segment details per Siemens Healthineers' press releases cited above. Competitive framing per trade-press coverage of the announcement.
The pattern this fits
Taken alone, one vendor trimming a product line isn't a trend. Taken as a capital-allocation decision by one of the industry's largest equipment makers — discontinue a diagnostic hardware category serving general radiology, fold the rest of ultrasound into a segment built around procedures and therapy, and target that segment for the company's best margin growth — it is a clean instance of where imaging capex is being pointed: toward the acquisition/procedural side of the pipeline, where a device vendor can own a differentiated, margin-rich niche, and away from commoditized diagnostic hardware.
That capital pattern runs in the opposite direction from where imaging demand is actually growing. The American College of Radiology's Harvey L. Neiman Health Policy Institute projects CT volume could rise by as much as 25% by 2055, against a radiologist workforce projected to grow only about 21% over the same period even if attrition holds at today's already-elevated rate — radiologist attrition more than doubled from 1.1% in 2014 to 2.5% in 2022, per the institute's workforce update. More studies are coming; the people who have to read and report them are not growing to match. Equipment vendors are free to chase the hardware segment with the best margins — that's a rational business decision — but it leaves the reporting layer as the part of the pipeline nobody with a capital-equipment budget is racing to fund.
Where xAID fits
xAID isn't in the ultrasound business, and this isn't a story about any single modality. It's a story about where imaging money goes when a vendor gets to choose, and the answer — procedural and therapy hardware, not diagnostic reporting capacity — is exactly the gap xAID's AI CT reporting is built to address from the software side: it drafts a structured, comprehensive report the moment a CT study is acquired, an in-house radiologist reviews every preliminary, and the result is delivered ready-to-sign for the reading radiologist. No capital-equipment budget has to grow for reporting throughput to grow.
Frequently asked questions
What is Siemens Healthineers stopping, and when?
As of October 12, 2026, Siemens Healthineers stopped selling its general imaging ultrasound systems — the Acuson Sequoia, Redwood, Juniper and Maple. It continues to support existing installed systems with maintenance, software updates and transducer availability, and continues to sell procedural ultrasound systems: the Acuson Origin, P500 intracardiac echocardiography (ICE) system, and Freestyle, used mainly by electrophysiologists and interventional cardiologists.
Why is Siemens Healthineers exiting general-imaging ultrasound?
Siemens Healthineers has never led the conventional ultrasound market — Philips, GE HealthCare, Fujifilm and Canon have long held that position — and trade press covering the exit linked that scale disadvantage to weaker margins in general imaging specifically. Ultrasound head Sourabh Pagaria framed the move around imaging becoming part of therapy, not just diagnosis, concentrating resources on procedural imaging where Siemens has more than 25 years in intracardiac echocardiography.
How does the ultrasound exit fit Siemens Healthineers' broader strategy?
In November 2025, Siemens Healthineers announced a reorganization into three segments as part of its 'Elevating Health Globally' plan: Imaging (prevention and detection), Precision Therapy (treatment — combining Varian radiation oncology, Advanced Therapies and ultrasound), and Diagnostics. Precision Therapy is targeted for high-single-digit annual revenue growth and roughly 100 basis points of margin improvement a year through fiscal 2030. Ultrasound generated just over €600 million in 2025, about 9% of that new segment's revenue.
What does this say about where imaging capital is going?
It is one more data point that capital-equipment investment in imaging is tilting toward procedural and image-guided-therapy hardware — higher margin, more defensible — rather than toward the diagnostic reporting side of the pipeline. The ACR's Harvey L. Neiman Health Policy Institute separately projects CT volume could grow as much as 25% by 2055 while the radiologist workforce grows only about 21%, even if attrition stays at today's elevated rate. Equipment vendors are consolidating around procedures; reporting capacity is not seeing a comparable wave of investment.
Source: Siemens Healthineers ultrasound announcement and Capital Markets Day strategy announcement, as reported by Radiology Business, AuntMinnie, Becker's Hospital Review and ad-hoc-news. Radiologist-workforce figures from the ACR Harvey L. Neiman Health Policy Institute's 2026 workforce update. Figures are rounded as reported.